Opportunities in Evidence Generation for Tumor-agnostic Targeted Therapies to Better Support Health Technology Assessments in Europe
Tumor-agnostic therapies are among the most challenging for regulators and health technology assessment (HTA) bodies to assess. Uncertainty in evidence packages, caused by factors such as small heterogeneous populations, are not typically an issue with tumor-specific drugs. This whitepaper explores how wider use of Real World Evidence can support faster and more sustainable access to patients.
If you would like to continue the conversation with an expert at IQVIA, please fill out the form below.
By selecting this box, I consent to receiving marketing communications and information about IQVIA's offering by email.

Copyright © 2026 IQVIA Holdings Inc. and its affiliates. All rights reserved. Privacy Statement

DO NOT SELL MY PERSONAL INFORMATION